Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Benzinga Newsdesk www.benzinga.com Positive 77.2%

Neg 0% Neu 0% Pos 77.2%

Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.